{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:41:25Z","timestamp":1792456885877,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81602266"],"award-info":[{"award-number":["81602266"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007300","name":"China Medical University","doi-asserted-by":"publisher","award":["XZR20160001"],"award-info":[{"award-number":["XZR20160001"]}],"id":[{"id":"10.13039\/501100007300","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.gene.2017.09.009","type":"journal-article","created":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T13:46:16Z","timestamp":1504705576000},"page":"3-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Fascaplysin inhibit ovarian cancer cell proliferation and metastasis through inhibiting CDK4"],"prefix":"10.1016","volume":"635","author":[{"given":"Shuo","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Bo","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3226-8127","authenticated-orcid":false,"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gene.2017.09.009_bb0005","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.gene.2017.09.009_bb0010","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/1947601913478972","article-title":"CDK4: a key player in the cell cycle, development, and cancer","volume":"3","author":"Baker","year":"2012","journal-title":"Genes Cancer"},{"key":"10.1016\/j.gene.2017.09.009_bb0015","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ng.619","article-title":"Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy","volume":"42","author":"Barretina","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.gene.2017.09.009_bb0020","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00432-011-1039-4","article-title":"The CDK inhibitors in cancer research and therapy","volume":"137","author":"Cicenas","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.gene.2017.09.009_bb0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies","volume":"16","author":"Delbridge","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.gene.2017.09.009_bb0030","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1684\/bdc.2011.1467","article-title":"The serine\/threonine kinases that control cell cycle progression as therapeutic targets","volume":"98","author":"Diallo","year":"2011","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.gene.2017.09.009_bb0035","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s10637-009-9236-6","article-title":"Cyclin-dependent kinase inhibitors as potential targeted anticancer agents","volume":"27","author":"Diaz-Padilla","year":"2009","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.gene.2017.09.009_bb0040","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1158\/1078-0432.CCR-13-1551","article-title":"Molecular pathways: CDK4 inhibitors for cancer therapy","volume":"20","author":"Dickson","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.gene.2017.09.009_bb0045","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12033-008-9126-8","article-title":"Functional evolution of cyclin-dependent kinases","volume":"42","author":"Doonan","year":"2009","journal-title":"Mol. Biotechnol."},{"issue":"3","key":"10.1016\/j.gene.2017.09.009_bb0050","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s13402-017-0316-x","article-title":"Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss","volume":"40","author":"Gao","year":"2017","journal-title":"Cell. Oncol. (Dordr.)."},{"key":"10.1016\/j.gene.2017.09.009_bb0055","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10549-005-9066-y","article-title":"Validation of cyclin D1\/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression","volume":"95","author":"Grillo","year":"2006","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.gene.2017.09.009_bb0060","article-title":"Galectin-3 supports stemness in ovarian cancer stem cells by activation of the Notch1 intracellular domain","author":"Gu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.gene.2017.09.009_bb0065","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/md12031377","article-title":"Cytotoxic effects of fascaplysin against small cell lung cancer cell lines","volume":"12","author":"Hamilton","year":"2014","journal-title":"Mar. Drugs."},{"key":"10.1016\/j.gene.2017.09.009_bb0070","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0968-0896(00)00313-8","article-title":"DNA binding properties of the marine sponge pigment fascaplysin","volume":"9","author":"Hormann","year":"2001","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.gene.2017.09.009_bb0075","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1158\/1078-0432.CCR-08-3185","article-title":"Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas","volume":"15","author":"Italiano","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.gene.2017.09.009_bb0080","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","article-title":"Antiangiogenic therapy in oncology: current status and future directions","volume":"388","author":"Jayson","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.gene.2017.09.009_bb0085","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/jcb.25053","article-title":"Fascaplysin induces caspase mediated crosstalk between apoptosis and autophagy through the inhibition of PI3K\/AKT\/mTOR signaling cascade in human leukemia HL-60 cells","volume":"116","author":"Kumar","year":"2015","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.gene.2017.09.009_bb0090","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrd2907","article-title":"Cell cycle kinases as therapeutic targets for cancer","volume":"8","author":"Lapenna","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.gene.2017.09.009_bb0095","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00280-006-0282-x","article-title":"Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivo","volume":"59","author":"Lin","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.gene.2017.09.009_bb0100","first-page":"980","article-title":"Anti-proliferation of human cervical cancer HeLa cell line by fascaplysin through apoptosis induction","volume":"44","author":"Lu","year":"2009","journal-title":"Yao Xue Xue Bao."},{"key":"10.1016\/j.gene.2017.09.009_bb0105","doi-asserted-by":"crossref","first-page":"e1743","DOI":"10.1038\/cddis.2015.96","article-title":"Antitumour potential of BPT: a dual inhibitor of cdk4 and tubulin polymerization","volume":"6","author":"Mahale","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.gene.2017.09.009_bb0110","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3892\/ijo.2015.3097","article-title":"Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma","volume":"47","author":"Mahgoub","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.gene.2017.09.009_bb0115","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/35106065","article-title":"To cycle or not to cycle: a critical decision in cancer","volume":"1","author":"Malumbres","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.gene.2017.09.009_bb0120","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ccr.2005.12.026","article-title":"Is cyclin D1-CDK4 kinase a bona fide cancer target?","volume":"9","author":"Malumbres","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.gene.2017.09.009_bb0125","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.gde.2006.12.008","article-title":"Cell cycle kinases in cancer","volume":"17","author":"Malumbres","year":"2007","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.gene.2017.09.009_bb0130","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs, and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.gene.2017.09.009_bb0135","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/374131a0","article-title":"Principles of CDK regulation","volume":"374","author":"Morgan","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.gene.2017.09.009_bb0140","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/2159-8290.CD-16-0095","article-title":"Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors","volume":"6","author":"Patnaik","year":"2016","journal-title":"Cancer Discov."},{"issue":"Suppl. 1","key":"10.1016\/j.gene.2017.09.009_bb0145","doi-asserted-by":"crossref","first-page":"i53","DOI":"10.1093\/annonc\/mdw087","article-title":"Mucinous epithelial ovarian carcinoma","volume":"27","author":"Perren","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.gene.2017.09.009_bb0150","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-0-387-68969-2_7","article-title":"Ovarian carcinogenesis: an alternative hypothesis","volume":"622","author":"Piek","year":"2008","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.gene.2017.09.009_bb0155","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1021\/np049935+","article-title":"Comparison of Fascaplysin and related alkaloids: a study of structures, cytotoxicities, and sources","volume":"67","author":"Segraves","year":"2004","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.gene.2017.09.009_bb0160","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1200\/JCO.2005.03.7689","article-title":"Cyclin-dependent kinase pathways as targets for cancer treatment","volume":"24","author":"Shapiro","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gene.2017.09.009_bb0165","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1158\/1078-0432.CCR-13-0259","article-title":"The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma","volume":"19","author":"Sheppard","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.gene.2017.09.009_bb0170","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1006\/gyno.2000.5961","article-title":"Inverse expression of Cdk4 and p16 in epithelial ovarian tumors","volume":"79","author":"Sui","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gene.2017.09.009_bb0175","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.neuron.2007.05.018","article-title":"Caspase-3 cleavage of GGA3 stabilizes BACE: implications for Alzheimer's disease","volume":"54","author":"Vassar","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.gene.2017.09.009_bb0180","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ccr.2005.12.012","article-title":"Requirement for CDK4 kinase function in breast cancer","volume":"9","author":"Yu","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.gene.2017.09.009_bb0185","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.biopha.2009.04.046","article-title":"Direct effects of fascaplysin on human umbilical vein endothelial cells attributing the anti-angiogenesis activity","volume":"64","author":"Zheng","year":"2010","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.gene.2017.09.009_bb0190","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/ng0196-97","article-title":"Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma","volume":"12","author":"Zuo","year":"1996","journal-title":"Nat. Genet."}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111917307187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111917307187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T01:29:08Z","timestamp":1570066148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111917307187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":38,"alternative-id":["S0378111917307187"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2017.09.009","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fascaplysin inhibit ovarian cancer cell proliferation and metastasis through inhibiting CDK4","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2017.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}